FDA Unveils 'PreCheck' to Expedite Drug Manufacturing; AstraZeneca and Acadia Face Regulatory Hurdles
The FDA launches a new program to fast-track reviews for strategically important drug manufacturing facilities. In separate developments, AstraZeneca faces a setback for a lupus drug formulation, while Acadia Pharmaceuticals receives a negative signal from European regulators for its Rett syndrome therapy.